Symbols / UTHR Stock $567.16 -0.99% United Therapeutics Corporation

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
UTHR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph…
Exch · Country NMS · United States
Market Cap 24.86B
Enterprise Value 21.97B
Income 1.33B
Sales 3.18B
FCF (ttm) 583.20M
Book/sh 162.60
Cash/sh 66.63
Employees 1,400
Insider 10d —
IPO Jun 17, 1999
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 20.36
Forward P/E 16.66
PEG 2.26
P/S 7.81
P/B 3.49
P/C —
EV/EBITDA 13.71
EV/Sales 6.90
Quick Ratio 5.83
Current Ratio 6.61
Debt/Eq 0.53
LT Debt/Eq —
EPS (ttm) 27.85
EPS next Y 34.05
EPS Growth 24.50%
Revenue Growth 7.40%
EPS Gr Q/Q 20.90%
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-02-25
ROA 12.44%
ROE 19.71%
ROIC —
Gross Margin 87.92%
Oper. Margin 45.23%
Profit Margin 41.94%
Shs Outstand 43.83M
Shs Float 40.32M
Insider Own 1.94%
Instit Own 97.83%
Short Float 8.18%
Short Ratio 4.23
Short Interest 2.70M
52W High 607.89
vs 52W High -6.70%
52W Low 272.12
vs 52W Low 108.42%
Beta 0.75
Impl. Vol. 48.19%
Rel Volume 0.48
Avg Volume 522.78K
Volume 250.51K
Target (mean) $644.62
Tgt Median $660.00
Tgt Low $519.00
Tgt High $733.00
# Analysts 13
Recom Buy
Prev Close $572.85
Price $567.16
Change -0.99%
About

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$644.62
Mean price target
2. Current target
$567.16
Latest analyst target
3. DCF / Fair value
$239.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$567.16
Low
$519.00
High
$733.00
Mean
$644.62

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-10 main Morgan Stanley Equal-Weight → Equal-Weight $519
2026-03-31 main HC Wainwright & Co. Buy → Buy $660
2026-03-31 main Wells Fargo Equal-Weight → Equal-Weight $575
2026-03-31 main B of A Securities Neutral → Neutral $626
2026-03-30 main TD Cowen Buy → Buy $660
2026-03-23 main Wells Fargo Equal-Weight → Equal-Weight $486
2026-03-12 main Cantor Fitzgerald Overweight → Overweight $625
2026-03-05 main UBS Buy → Buy $705
2026-02-26 main HC Wainwright & Co. Buy → Buy $600
2026-02-26 main TD Cowen Buy → Buy $575
2026-02-26 main Oppenheimer Outperform → Outperform $600
2026-02-26 main RBC Capital Outperform → Outperform $643
2026-02-26 main Wells Fargo Equal-Weight → Equal-Weight $466
2026-01-06 main UBS Buy → Buy $645
2025-11-06 main UBS Buy → Buy $600
2025-10-30 main HC Wainwright & Co. Buy → Buy $525
2025-10-30 main RBC Capital Outperform → Outperform $587
2025-10-30 main Wells Fargo Equal-Weight → Equal-Weight $423
2025-10-10 main Morgan Stanley Equal-Weight → Equal-Weight $435
2025-09-29 main UBS Buy → Buy $580
News
RSS: Latest UTHR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-22 ROTHBLATT MARTINE A Chief Executive Officer — 9,500 $572.48 $5,477,366
2026-04-22 ROTHBLATT MARTINE A Chief Executive Officer — 9,500 $146.03 $1,387,285
2026-04-21 ROTHBLATT MARTINE A Chief Executive Officer — 9,500 $564.35 $5,419,006
2026-04-21 ROTHBLATT MARTINE A Chief Executive Officer — 9,500 $146.03 $1,387,285
2026-04-20 EDGEMOND JAMES Chief Financial Officer — 10,000 $572.33 $5,778,607
2026-04-20 EDGEMOND JAMES Chief Financial Officer — 10,000 $135.42 $1,354,200
2026-04-20 ROTHBLATT MARTINE A Chief Executive Officer — 9,500 $572.41 $5,489,424
2026-04-20 ROTHBLATT MARTINE A Chief Executive Officer — 9,500 $146.03 $1,387,285
2026-04-17 PATUSKY CHRISTOPHER Director — 1,000 $578.88 $578,880
2026-04-17 PATUSKY CHRISTOPHER Director — 1,000 $101.80 $101,800
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
3,182.70
+10.61%
2,877.40
+23.63%
2,327.50
+20.20%
1,936.30
Operating Revenue
3,182.70
+10.61%
2,877.40
+23.63%
2,327.50
+20.20%
1,936.30
Cost Of Revenue
384.40
+24.12%
309.70
+20.27%
257.50
+69.85%
151.60
Reconciled Cost Of Revenue
384.40
+24.12%
309.70
+20.27%
257.50
+69.85%
151.60
Gross Profit
2,798.30
+8.98%
2,567.70
+24.04%
2,070.00
+15.99%
1,784.70
Operating Expense
1,281.10
+14.42%
1,119.60
+26.49%
885.10
+9.95%
805.00
Research And Development
550.00
+14.35%
481.00
+17.89%
408.00
+26.35%
322.90
Selling General And Administration
731.10
+14.48%
638.60
+33.85%
477.10
-1.04%
482.10
Selling And Marketing Expense
118.60
+23.16%
96.30
+17.73%
81.80
+15.54%
70.80
General And Administrative Expense
612.50
+12.94%
542.30
+37.19%
395.30
-3.89%
411.30
Salaries And Wages
111.50
+1.83%
109.50
+418.96%
21.10
-72.98%
78.10
Other Gand A
501.00
+15.76%
432.80
+15.66%
374.20
+12.30%
333.20
Total Expenses
1,665.50
+16.53%
1,429.30
+25.09%
1,142.60
+19.44%
956.60
Operating Income
1,517.20
+4.77%
1,448.10
+22.21%
1,184.90
+20.95%
979.70
Total Operating Income As Reported
1,492.50
+8.39%
1,377.00
+16.21%
1,184.90
+20.95%
979.70
EBITDA
1,819.00
+9.95%
1,654.40
+19.30%
1,386.80
+34.08%
1,034.30
Normalized EBITDA
1,843.70
+6.85%
1,725.50
+24.42%
1,386.80
+33.86%
1,036.00
Reconciled Depreciation
85.60
+18.07%
72.50
+36.28%
53.20
+3.70%
51.30
EBIT
1,733.40
+9.58%
1,581.90
+18.62%
1,333.60
+35.67%
983.00
Total Unusual Items
-24.70
+65.26%
-71.10
0.00
+100.00%
-1.70
Total Unusual Items Excluding Goodwill
-24.70
+65.26%
-71.10
0.00
+100.00%
-1.70
Special Income Charges
-24.70
+65.26%
-71.10
0.00
+100.00%
-1.70
Other Special Charges
3.00
-95.78%
71.10
—
—
Impairment Of Capital Assets
21.70
0.00
0.00
—
Write Off
—
0.00
0.00
-100.00%
1.70
Net Income
1,334.70
+11.68%
1,195.10
+21.35%
984.80
+35.40%
727.30
Pretax Income
1,713.90
+11.36%
1,539.00
+20.77%
1,274.30
+34.05%
950.60
Net Non Operating Interest Income Expense
172.50
+10.44%
156.20
+51.06%
103.40
+707.81%
12.80
Interest Expense Non Operating
19.50
-54.55%
42.90
-27.66%
59.30
+83.02%
32.40
Net Interest Income
172.50
+10.44%
156.20
+51.06%
103.40
+707.81%
12.80
Interest Expense
19.50
-54.55%
42.90
-27.66%
59.30
+83.02%
32.40
Interest Income Non Operating
192.00
-3.57%
199.10
+22.37%
162.70
+259.96%
45.20
Interest Income
192.00
-3.57%
199.10
+22.37%
162.70
+259.96%
45.20
Other Income Expense
24.20
+137.06%
-65.30
-366.43%
-14.00
+66.59%
-41.90
Other Non Operating Income Expenses
48.90
+743.10%
5.80
+141.43%
-14.00
+65.17%
-40.20
Tax Provision
379.20
+10.26%
343.90
+18.79%
289.50
+29.65%
223.30
Tax Rate For Calcs
0.00
-1.10%
0.00
-1.64%
0.00
-1.22%
0.00
Tax Effect Of Unusual Items
-5.46
+65.64%
-15.89
0.00
+100.00%
-0.39
Net Income Including Noncontrolling Interests
1,334.70
+11.68%
1,195.10
+21.35%
984.80
+35.40%
727.30
Net Income From Continuing Operation Net Minority Interest
1,334.70
+11.68%
1,195.10
+21.35%
984.80
+35.40%
727.30
Net Income From Continuing And Discontinued Operation
1,334.70
+11.68%
1,195.10
+21.35%
984.80
+35.40%
727.30
Net Income Continuous Operations
1,334.70
+11.68%
1,195.10
+21.35%
984.80
+35.40%
727.30
Normalized Income
1,353.94
+8.29%
1,250.31
+26.96%
984.80
+35.16%
728.61
Net Income Common Stockholders
1,334.70
+11.68%
1,195.10
+21.35%
984.80
+35.40%
727.30
Diluted EPS
27.86
+13.07%
24.64
+24.38%
19.81
+32.07%
15.00
Basic EPS
30.13
+13.96%
26.44
+25.67%
21.04
+31.66%
15.98
Basic Average Shares
44.30
-1.99%
45.20
-3.42%
46.80
+2.86%
45.50
Diluted Average Shares
47.90
-1.24%
48.50
-2.41%
49.70
+2.47%
48.50
Diluted NI Availto Com Stockholders
1,334.70
+11.68%
1,195.10
+21.35%
984.80
+35.40%
727.30
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
7,880.00
+7.01%
7,364.00
+2.75%
7,167.00
+18.57%
6,044.50
Current Assets
3,702.50
-4.42%
3,873.90
+9.09%
3,551.00
+5.05%
3,380.30
Cash And Cash Equivalents
1,557.10
-8.25%
1,697.20
+40.53%
1,207.70
+25.65%
961.20
Other Short Term Investments
1,363.20
-13.16%
1,569.80
-12.12%
1,786.40
-4.85%
1,877.50
Receivables
350.20
+25.38%
279.30
+0.14%
278.90
+26.54%
220.40
Accounts Receivable
350.20
+25.38%
279.30
+0.14%
278.90
+26.54%
220.40
Inventory
183.10
+15.96%
157.90
+41.23%
111.80
+9.61%
102.00
Raw Materials
30.60
+6.99%
28.60
+31.80%
21.70
+20.56%
18.00
Work In Process
35.30
+2.92%
34.30
-0.29%
34.40
+3.30%
33.30
Finished Goods
117.20
+23.37%
95.00
+70.56%
55.70
+9.86%
50.70
Other Current Assets
248.90
+46.67%
169.70
+2.11%
166.20
-24.18%
219.20
Total Non Current Assets
4,177.50
+19.70%
3,490.10
-3.48%
3,616.00
+35.73%
2,664.20
Net PPE
1,729.70
+41.50%
1,222.40
+16.93%
1,045.40
+21.35%
861.50
Gross PPE
2,297.50
+34.07%
1,713.60
+16.29%
1,473.60
+18.44%
1,244.20
Accumulated Depreciation
-567.80
-15.59%
-491.20
-14.71%
-428.20
-11.89%
-382.70
Properties
0.00
0.00
0.00
0.00
Land And Improvements
266.50
+46.51%
181.90
+22.91%
148.00
+3.71%
142.70
Buildings And Improvements
944.70
+9.37%
863.80
+26.05%
685.30
+7.63%
636.70
Machinery Furniture Equipment
493.60
+9.76%
449.70
+17.97%
381.20
+7.71%
353.90
Construction In Progress
592.70
+171.63%
218.20
-15.79%
259.10
+133.63%
110.90
Goodwill And Other Intangible Assets
116.50
+4.11%
111.90
-2.01%
114.20
+156.63%
44.50
Goodwill
32.30
+0.00%
32.30
-4.15%
33.70
+20.36%
28.00
Other Intangible Assets
84.20
+5.78%
79.60
-1.12%
80.50
+387.88%
16.50
Investments And Advances
1,776.70
+20.43%
1,475.30
-22.75%
1,909.80
+45.10%
1,316.20
Non Current Deferred Assets
357.70
-21.97%
458.40
+16.11%
394.80
+20.48%
327.70
Non Current Deferred Taxes Assets
357.70
-21.97%
458.40
+16.11%
394.80
+20.48%
327.70
Other Non Current Assets
196.90
-11.35%
222.10
+46.31%
151.80
+32.81%
114.30
Total Liabilities Net Minority Interest
783.80
-14.80%
920.00
-22.18%
1,182.20
-5.26%
1,247.80
Current Liabilities
560.60
-24.05%
738.10
-8.24%
804.40
+134.38%
343.20
Payables And Accrued Expenses
488.00
+41.65%
344.50
+15.60%
298.00
+29.62%
229.90
Payables
7.10
+18.33%
6.00
+7.14%
5.60
+36.59%
4.10
Accounts Payable
7.10
+18.33%
6.00
+7.14%
5.60
+36.59%
4.10
Current Accrued Expenses
480.90
+42.07%
338.50
+15.77%
292.40
+29.50%
225.80
Pensionand Other Post Retirement Benefit Plans Current
0.00
-100.00%
11.00
-68.93%
35.40
-56.19%
80.80
Current Debt And Capital Lease Obligation
—
300.00
-25.00%
400.00
—
Current Debt
—
300.00
-25.00%
400.00
—
Other Current Borrowings
—
300.00
-25.00%
400.00
—
Other Current Liabilities
72.60
-12.11%
82.60
+16.34%
71.00
+118.46%
32.50
Total Non Current Liabilities Net Minority Interest
223.20
+22.70%
181.90
-51.85%
377.80
-58.24%
904.60
Long Term Debt And Capital Lease Obligation
—
—
300.00
-62.50%
800.00
Long Term Debt
—
—
300.00
-62.50%
800.00
Other Non Current Liabilities
223.20
+22.70%
181.90
+133.80%
77.80
-25.62%
104.60
Stockholders Equity
7,096.20
+10.12%
6,444.00
+7.67%
5,984.80
+24.77%
4,796.70
Common Stock Equity
7,096.20
+10.12%
6,444.00
+7.67%
5,984.80
+24.77%
4,796.70
Capital Stock
0.80
+0.00%
0.80
+14.29%
0.70
+0.00%
0.70
Common Stock
0.80
+0.00%
0.80
+14.29%
0.70
+0.00%
0.70
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
76.45
+1.94%
75.00
+1.82%
73.66
+1.39%
72.65
Ordinary Shares Number
43.64
-2.65%
44.83
-4.70%
47.04
+2.19%
46.03
Treasury Shares Number
32.81
+8.76%
30.17
+13.33%
26.62
+0.00%
26.62
Additional Paid In Capital
2,798.00
+3.67%
2,698.90
+5.88%
2,549.00
+6.72%
2,388.40
Retained Earnings
8,556.90
+18.48%
7,222.20
+19.83%
6,027.10
+19.53%
5,042.30
Gains Losses Not Affecting Retained Earnings
0.90
+126.47%
-3.40
+73.44%
-12.80
+76.94%
-55.50
Treasury Stock
4,260.40
+22.62%
3,474.50
+34.71%
2,579.20
+0.00%
2,579.20
Other Equity Adjustments
0.90
+126.47%
-3.40
+73.44%
-12.80
+76.94%
-55.50
Total Equity Gross Minority Interest
7,096.20
+10.12%
6,444.00
+7.67%
5,984.80
+24.77%
4,796.70
Total Capitalization
7,096.20
+10.12%
6,444.00
+2.53%
6,284.80
+12.29%
5,596.70
Working Capital
3,141.90
+0.19%
3,135.80
+14.17%
2,746.60
-9.57%
3,037.10
Invested Capital
7,096.20
+5.22%
6,744.00
+0.89%
6,684.80
+19.44%
5,596.70
Total Debt
—
300.00
-57.14%
700.00
-12.50%
800.00
Net Tangible Assets
6,979.70
+10.23%
6,332.10
+7.86%
5,870.60
+23.53%
4,752.20
Tangible Book Value
6,979.70
+10.23%
6,332.10
+7.86%
5,870.60
+23.53%
4,752.20
Available For Sale Securities
1,776.70
+20.43%
1,475.30
-22.75%
1,909.80
—
Investmentin Financial Assets
1,776.70
+20.43%
1,475.30
-22.75%
1,909.80
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
1,561.20
+17.64%
1,327.10
+35.70%
978.00
+21.87%
802.50
Cash Flow From Continuing Operating Activities
1,561.20
+17.64%
1,327.10
+35.70%
978.00
+21.87%
802.50
Net Income From Continuing Operations
1,334.70
+11.68%
1,195.10
+21.35%
984.80
+35.40%
727.30
Depreciation Amortization Depletion
85.60
+18.07%
72.50
+36.28%
53.20
+3.70%
51.30
Depreciation
84.70
+18.30%
71.60
+35.35%
52.90
+3.32%
51.20
Amortization Cash Flow
0.90
+0.00%
0.90
+200.00%
0.30
+200.00%
0.10
Depreciation And Amortization
85.60
+18.07%
72.50
+36.28%
53.20
+3.70%
51.30
Amortization Of Intangibles
0.90
+0.00%
0.90
+200.00%
0.30
+200.00%
0.10
Other Non Cash Items
-19.70
+18.93%
-24.30
-395.92%
-4.90
-109.33%
52.50
Stock Based Compensation
147.70
+2.57%
144.00
+268.29%
39.10
-63.39%
106.80
Asset Impairment Charge
21.70
0.00
-100.00%
3.60
-72.09%
12.90
Deferred Tax
97.70
+252.42%
-64.10
+0.47%
-64.40
—
Deferred Income Tax
97.70
+252.42%
-64.10
+0.47%
-64.40
—
Operating Gains Losses
—
—
—
-7.10
Gain Loss On Investment Securities
—
—
—
-7.10
Change In Working Capital
-106.50
-2830.77%
3.90
+111.68%
-33.40
+76.35%
-141.20
Change In Receivables
-70.90
-17625.00%
-0.40
+99.32%
-58.50
-169.59%
-21.70
Changes In Account Receivables
-70.90
-17625.00%
-0.40
+99.32%
-58.50
-169.59%
-21.70
Change In Inventory
-52.60
-12.15%
-46.90
-244.85%
-13.60
-1.49%
-13.40
Change In Payables And Accrued Expense
97.90
+129.27%
42.70
-25.22%
57.10
+28.31%
44.50
Change In Other Working Capital
-80.90
-1051.76%
8.50
+146.20%
-18.40
+87.78%
-150.60
Investing Cash Flow
-551.30
-232.14%
417.20
+157.98%
-719.60
+11.32%
-811.50
Cash Flow From Continuing Investing Activities
-551.30
-232.14%
417.20
+157.98%
-719.60
+11.32%
-811.50
Net PPE Purchase And Sale
-520.50
-111.16%
-246.50
-6.99%
-230.40
-65.99%
-138.80
Purchase Of PPE
-520.50
-111.16%
-246.50
-6.99%
-230.40
-65.99%
-138.80
Sale Of PPE
—
—
—
0.00
Capital Expenditure
-526.00
-113.39%
-246.50
-6.99%
-230.40
-65.99%
-138.80
Net Investment Purchase And Sale
40.10
-94.45%
722.70
+291.70%
-377.00
+44.12%
-674.70
Purchase Of Investment
-3,405.40
-106.88%
-1,646.10
+34.53%
-2,514.30
-47.16%
-1,708.60
Sale Of Investment
3,445.50
+45.45%
2,368.80
+10.83%
2,137.30
+106.72%
1,033.90
Net Business Purchase And Sale
-55.00
-80.33%
-30.50
+65.81%
-89.20
-5846.67%
-1.50
Purchase Of Business
-55.00
-80.33%
-30.50
+65.81%
-89.20
-5846.67%
-1.50
Net Intangibles Purchase And Sale
-5.50
0.00
0.00
—
Purchase Of Intangibles
-5.50
0.00
0.00
—
Net Other Investing Changes
-10.40
+63.51%
-28.50
-23.91%
-23.00
-757.14%
3.50
Financing Cash Flow
-1,150.00
+8.35%
-1,254.80
-10444.54%
-11.90
-115.78%
75.40
Cash Flow From Continuing Financing Activities
-1,150.00
+8.35%
-1,254.80
-10444.54%
-11.90
-115.78%
75.40
Net Issuance Payments Of Debt
-300.00
+25.00%
-400.00
-300.00%
-100.00
0.00
Issuance Of Debt
200.00
0.00
0.00
-100.00%
800.00
Repayment Of Debt
-500.00
-25.00%
-400.00
-300.00%
-100.00
+87.50%
-800.00
Long Term Debt Issuance
—
—
—
800.00
Long Term Debt Payments
—
—
—
-800.00
Net Long Term Debt Issuance
—
—
—
0.00
Short Term Debt Issuance
200.00
0.00
0.00
-100.00%
800.00
Short Term Debt Payments
-500.00
-25.00%
-400.00
-300.00%
-100.00
+87.50%
-800.00
Net Short Term Debt Issuance
-300.00
+25.00%
-400.00
-300.00%
-100.00
0.00
Net Common Stock Issuance
-1,016.60
-0.43%
-1,012.20
-7234.78%
-13.80
-21.05%
-11.40
Common Stock Payments
-1,016.60
-0.43%
-1,012.20
-7234.78%
-13.80
-21.05%
-11.40
Repurchase Of Capital Stock
-1,016.60
-0.43%
-1,012.20
-7234.78%
-13.80
-21.05%
-11.40
Proceeds From Stock Option Exercised
183.10
+14.37%
160.10
+53.06%
104.60
+10.92%
94.30
Net Other Financing Charges
-16.50
-511.11%
-2.70
+0.00%
-2.70
+64.00%
-7.50
Changes In Cash
-140.10
-128.62%
489.50
+98.58%
246.50
+271.23%
66.40
Beginning Cash Position
1,697.20
+40.53%
1,207.70
+25.65%
961.20
+7.42%
894.80
End Cash Position
1,557.10
-8.25%
1,697.20
+40.53%
1,207.70
+25.65%
961.20
Free Cash Flow
1,035.20
-4.20%
1,080.60
+44.54%
747.60
+12.64%
663.70
Interest Paid Supplemental Data
13.50
-66.42%
40.20
-28.21%
56.00
+92.44%
29.10
Sale Of Business
—
—
—
8.60
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category